Ligand Pharmaceuticals | LGND - Net Income


Ligand Pharmaceuticals reported $117.27M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Amgen USD 1.33B 1.88B Dec/2025
Arrowhead Research USD -23.75M 151.49M Sep/2025
Baxter International USD -46M 137M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
Insmed USD -370.02M 48.34M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Pacira USD 5.43M 10.28M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Veracyte USD 19.14M 20.12M Sep/2025